IBEX 35
11.105,50 +55,40 (+0,50%) Euro Stoxx 50
5.085,08 +30,67 (+0,61%) Dólar/Euro
1,0772 -0,0012 (-0,11%) Petróleo Brent
82,73 -1,15 (-1,37%) Oro
2.366,90 +26,60 (+1,14%) Bitcoin EUR
56.768,27 +27,33 (+0,05%)
Alto Neuroscience, Inc. (ANRO)
Después del cierre:
Alto Neuroscience, Inc.
369 South San Antonio Road
Los Altos, CA 94022
United States
650 200 0412
https://www.altoneuroscience.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Amit Etkin M.D., Ph.D. | Founder, Chairman of the Board, CEO & President | 705,65k | N/A | 1977 |
| Mr. Nicholas C. Smith | CFO & Secretary | 624,12k | N/A | 1989 |
| Mr. Adam Savitz M.D., Ph.D. | Chief Medical Officer | 579,57k | N/A | 1966 |
| Ms. Melissa Berman | Vice President of Finance & Accounting | N/A | N/A | 1980 |
| Ms. Erin R. McQuade J.D. | General Counsel & Chief Administrative Officer | N/A | N/A | 1975 |
| Ms. Jessica Powell | Chief Development Officer | N/A | N/A | 1975 |
| Mr. Fadi Abdel M.D. | Senior Vice President of Innovation | N/A | N/A | 1979 |
Descripción
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.
Gobierno corporativo
El ISS Governance QualityScore de Alto Neuroscience, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
